Chimeric antigen receptor T cell therapy - Hebei Senlang Biotechnology
Alternative Names: Auto CAR-T cells - Hebei Senlang Biotechnology; Autologous CAR-T - Hebei Senlang Biotechnology; BCMA CAR-T - Hebei Senlang Biotechnology; CAR-T cell therapy - Hebei Senlang Biotechnology; SENL-B-19Latest Information Update: 03 Jan 2023
Price :
$50 *
At a glance
- Originator Hebei Senlang Biotechnology
- Developer Hebei Medical University Fourth Hospital; Hebei Senlang Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Haematological malignancies
- Clinical Phase Unknown Hodgkin's disease; Leukaemia; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 03 Jan 2023 Clinical development is ongoing in China
- 11 Dec 2021 Efficacy and safety data from a phase I trial presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-2021)
- 22 Oct 2020 Clinical trials in Multiple myeloma (Second-line therapy or greater, Refractory metastatic disease) in China (Parenteral) (NCT04665076)